Angiotensin-converting enzyme inhibitors and prevention of adverse reactions.docVIP

 PAGE \* MERGEFORMAT 8 Angiotensin-converting enzyme inhibitors and prevention of adverse reactions Of: Shi Yulan, Zhang Xiahua and Wu Guang Tong [Abstract] Objective To observe the angiotensin converting enzyme inhibitor (ACEI clinical applications and prevention of adverse reactions to guide clinical treatment. Methods 346 cases were randomly divided into captopril group (116 patients, enalapril group ( 115 cases and Beiduopuli group (115 cases, the average treatment time of 4 weeks. observed the incidence of adverse reactions. the result of adverse reactions captopril group reached 23.2%, 15.6% according to that Puli Da, Beiduopuli 16.5% occurred in the medication 1 to 4 weeks, more women than men, more important than during the day and night, reduction or symptomatic treatment, the symptoms reduce or disappear. Conclusion Oral administration of ACEI drugs, the high incidence of adverse reactions, but if to detect given symptomatic treatment, and more can be tolerated, does not affect the medication. [Keywords:] angiotensin-converting enzyme inhibitors, adverse reactions, prevention Angiotensin-converting enzyme inhibitor (ACEI for more than 20 years of clinical history, is clinically used to treat one of the main drug for cardiovascular disease, but often cause adverse reactions because of their seriously restrict the clinical a wide range of applications. Based on the 346 cases of adverse reactions due to service patients with ACEI were analyzed to explore the mechanism of its occurrence in order to better guide clinical medication. 1 Materials and Methods 1.1 General Information 346 cases of hypertension and heart disease, of which 200 cases of essential hypertension, coronary heart disease of 116 cases, 20 cases of diabetic kidney disease, rheumatic heart disease (mitral and aortic valve replacement surgery, 6 cases of chronic pulmonary heart disease, 4 cases were randomly divided into captopril group (25 ~ 150mg/d116 patients: 64 ma